Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
Mohs microscopic surgery and image-guided superficial radiation therapy (IG-SRT) demonstrate high local cure rates in the management of non-melanoma skin cancer.
For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback